Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Exploratory, Phase II, Proof-of Concept, Clinical Study to Assess the Safety and Tolerability of EI-1071 in Patients With Alzheimer's Disease (AD)

NCT06745583 is registered in ClinicalTrials.gov with Elixiron Immunotherapeutics Inc. as lead sponsor.

NCT NCT06745583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06745583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Exploratory, Phase II, Proof-of Concept, Clinical Study to Assess the Safety and Tolerability of EI-1071 in Patients With Alzheimer's Disease (AD)
Lead sponsor
Elixiron Immunotherapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 16, 2024
Completion date
May 6, 2026
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mild, moderate, or severe alzheimer's disease